MexiB 6 tabs 125mg + 10mg #30

MexiB 6 instruction for use

Reed more and buy MexiB 6 here

Release form, composition and packaging

Tablets, film coated white or almost white, round, biconvex, almost white crosswise.
1 tab.
ethyl methyl hydroxypyridine succinate 125 mg
pyridoxine hydrochloride 10 mg
Excipients: calcium hydrophosphate dihydrate, copovidone, colloidal silicon dioxide (aerosil), croscarmellose sodium, magnesium lactate, magnesium stearate, hydrogenated castor oil, microcrystalline cellulose.

pharmachologic effect

MexiB 6 is a combination drug.
Ethyl methyl hydroxypyridine succinate, an inhibitor of free radical processes, is a membrane protector, which also has antihypoxic, stress protective, nootropic, antiepileptic and anxiolytic effects. Antioxidant drug that regulates metabolic processes in the myocardium and the vascular wall.
The mechanism of action is due to antioxidant and membrane-protective properties. Suppresses lipid peroxidation, increases the activity of superoxidase, affects the physicochemical properties of the membrane, increases the content of polar lipid fractions (phosphotidylserine and phosphotidyl inositol, etc.) in the membrane, reduces the cholesterol / phospholipid ratio, reduces the viscosity of the lipid layer and increases the membrane fluidity,
activates the energy-synthesizing functions of mitochondria and improves energy metabolism in the cell and, thus, protects the cell machinery and the structure of their membranes.
A change in the functional activity of a biological membrane caused by a preparation leads to conformational changes in protein macromolecules of synaptic membranes, as a result of which it has a modulating effect on the activity of membrane-bound enzymes, ion channels and receptor complexes, in particular, benzodiazepine, GABA, acetylcholine, enhancing their ability to bind to ligands, increasing the activity of neurotransmitters and activation of synaptic processes.
It enhances the compensatory activation of aerobic glycolysis and reduces the degree of inhibition of oxidative processes in the cycle
Krebs under hypoxic conditions with an increase in adenosine triphosphate (ATP) and creatine phosphate, activates the energy-synthesizing function of mitochondria.
Increases the body's resistance to the effects of various damaging factors in pathological conditions (shock, hypoxia and ischemia, cerebral circulation disorders, intoxication with ethanol and antipsychotic drugs). MexiB
6 improves metabolism and blood supply to the brain, microcirculation and rheological properties of blood, reduces platelet aggregation.
Stabilizes the membranes of blood cells (erythrocytes and platelets), reducing the likelihood of hemolysis. It has a hypolipidemic effect, reduces the content of total cholesterol and low lipoproteins
density (LDL).
It improves the functional state of ischemic myocardium, reducing manifestations of systolic and diastolic dysfunction of the left ventricle (LV), as well as electrical instability of the myocardium.
Under conditions of critical reduction of coronary blood flow, it contributes to the preservation of the structural and functional organization of cardiomyocyte membranes, stimulates the activity of phosphodiesterase membrane enzymes, adenylate cyclase, acetylcholinesterase. It supports the activation of aerobic glycolysis that develops during acute ischemia and, under hypoxic conditions, helps to restore mitochondrial redox processes, increases the synthesis of adenosine triphosphoric acid (ATP), creatine phosphate and other macroergs. Increases collateral blood supply of ischemic myocardium and activates energy-synthesizing processes in the ischemic zone, which contributes to preserving the integrity of cardiomyocytes and maintaining their functional activity.
In patients with stable angina, MexiB 6 is increases exercise tolerance and antianginal activity of nitrates, improves the rheological properties of blood, and reduces the incidence of acute coronary insufficiency.
Pyridoxine, entering the body, phosphorylates, turns into pyridoxal-5-phosphate and is part of the enzymes that carry out decarboxylation, transamination and racemization of amino acids, as well as the enzymatic transformation of sulfur-containing and hydroxylated amino acids. Participates in the metabolism; necessary for the normal functioning of the central and peripheral nervous system. Pyridoxine is involved in the metabolism of tryptophan, methionine, cysteine, glutamine and other amino acids. Plays an important role in histamine metabolism. Contributes to the normalization of lipid metabolism.

Pharmacokinetics

Ethyl methyl hydroxypyridine succinate is rapidly absorbed when taken orally (the period of semi-absorption is 0.08-1 h). The time to reach the maximum concentration (TCmax) by ingestion is 0.46-0.5 hours. The maximum concentration (Cmax) by ingestion is 50-100 ng / ml.
Rapidly distributed in organs and tissues. The average retention time of ethylmethylhydroxypyridine succinate in the body when taken orally is 4.9-5.2 h.
Ethyl methyl hydroxypyridine succinate is metabolized in the liver by glucuronidation. 5 metabolites have been identified: 3-hydroxypyridine phosphate - formed in the liver and, with the participation of alkaline phosphatase, decomposes into phosphoric acid and 3-hydroxy pyridine; The 2nd metabolite is pharmacologically active, it is formed in large quantities and is found in the urine for 1-2 days after administration; 3rd is excreted in large quantities with urine; The 4th and 5th glucuronujugates.
T1 / 2 when administered orally - 4.7-5 hours. It is rapidly excreted in the urine mainly as metabolites (50% in 12 hours) and in small quantities in unchanged form (0.3% in 12 hours). It is most intensively excreted during the first 4 hours after administration of ethyl methyl hydroxypyridine succinate. Indicators of urine excretion of unchanged ethylmethylhydroxypyridine succinate and metabolites have significant individual variability.
Pyridoxine is absorbed rapidly throughout the small intestine.
Metabolized in the liver to form pharmacologically active metabolites (pyridoxal phosphate and pyridoxamine phosphate).
Pyridoxal phosphate binds to plasma proteins by 90%. It penetrates well into all tissues; accumulates mainly in the liver, less - in the muscles and the central nervous system (CNS). Penetrates the placenta, is secreted with breast milk.
The half-life (T1 / 2) is 15-20 days. Excreted by the kidneys (when administered intravenously - with bile 2%), as well as during hemodialysis.

Indications for MexiB 6

As part of combination therapy:
- dyscirculatory encephalopathy;
- vegetative dystonia syndrome;
- anxiety states in neurotic and neurosis-like states;
- withdrawal syndrome in alcoholism with a predominance of neurosis-like and vegetative-vascular disorders;
- ischemic heart disease (prevention of seizures);
- conditions after acute intoxication with antipsychotics;
- asthenic conditions, as well as for the prevention of the development of somatic diseases under the influence of extreme factors and loads;
- the impact of extreme (stress) factors.

Contraindications

- hypersensitivity;
- acute hepatic and / or renal failure;
- pregnancy;
- lactation;
- childhood.

Carefully

- peptic ulcer of the stomach and duodenum.

Dosage

Inside, on 1 tablet of MexiB 6 3 times a day; The initial dose of 1-2 tablets 1-2 times a day with a gradual increase to obtain a therapeutic effect. The maximum daily dose of 6 tablets. / Day.
The duration of treatment is 2-8 weeks. If necessary, repeat courses are possible.

Side effects of MexiB 6

Nausea, dry mouth, diarrhea, drowsiness, allergic reactions, hypersecretion of hydrochloric acid, numbness, the appearance of a feeling of pressure in the extremities - a symptom of "stockings" and "gloves", reduced lactation (sometimes it is used as a therapeutic effect).

Overdose

Ethyl methyl hydroxypyridine succinate

Due to low toxicity, overdose is unlikely. In case of accidental overdose, drowsiness and sedation may occur. Treatment is usually not required - the symptoms disappear on their own within 24 hours. In severe cases of insomnia, nitrazepam 10 mg, oxazepam 10 mg or diazepam 5 mg.

Pyridoxine

Taking high doses of pyridoxine for a short period of time (at a dose of more than 1 g per day) can lead to a short-term neurotoxic effects.
When taking pyridoxine in a dose exceeding 150 mg / kg of body weight, it is recommended to induce vomiting and take activated charcoal. Provocation of vomiting is most effective during the first 30 minutes after taking MexiB 6. Emergency measures may be required.

Drug interaction

Ethyl methyl hydroxypyridine succinate

Enhances the action of benzodiazepine anxiolytics, antiepileptic (carbamazepine), anti-Parkinsonian drugs (levodopa), nitrates. Reduces the toxic effects of ethanol.

Pyridoxine

Enhances the effect of diuretics; weakens the activity of levodopa, goes well with heart
glycosides (pyridoxine enhances the synthesis of contractile proteins in the myocardium), with glutamic acid and potassium and magnesium asparaginate (resistance to hypoxia increases).
Pyridoxine is pharmaceutically incompatible with thiamine and cyanocobalamin. Isoniazid, penicillamine, cycloserine and estrogen-containing oral contraceptives weaken the effect of pyridoxine.

special instructions for MexiB 6

Influence on ability to drive vehicles and mechanisms

During the period of treatment, care must be taken when driving vehicles and engaging in other potentially hazardous activities that require increased concentration and psychomotor speed.

Pregnancy and lactation

Contraindicated in pregnancy and lactation.

Use in childhood

Contraindicated to children

In case of impaired renal function

Contraindicated in acute renal failure

With abnormal liver function

Contraindicated in acute liver failure

Pharmacy sales terms

You don't need a prescription to buy MexiB 6.

Terms and conditions of storage

In a dry, dark place at a temperature not higher than 25 ° C. Keep out of the reach of children. Shelf life - 2 years.